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Background: Ethnic and religious minorities have been disproportionately affected by SARS-CoV-2 world-
wide. The UK strictly-Orthodox Jewish community has been severely affected by the pandemic. This group
shares characteristics with other ethnic minorities including larger family sizes, higher rates of household
crowding and relative socioeconomic deprivation. We studied a UK strictly-Orthodox Jewish population to
understand transmission of COVID-19 within this community.
Methods: We performed a household-focused cross-sectional SARS-CoV-2 serosurvey between late-October
and early December 2020 prior to the third national lockdown. Randomly-selected households completed a
standardised questionnaire and underwent serological testing with a multiplex assay for SARS-CoV-2 IgG
antibodies. We report clinical illness and testing before the serosurvey, seroprevalence stratified by age and
sex. We used random-effects models to identify factors associated with infection and antibody titres.
Findings: A total of 343 households, consisting of 1,759 individuals, were recruited. Serum was available for
1,242 participants. The overall seroprevalence for SARS-CoV-2 was 64.3% (95% CI 61.6-67.0%). The lowest
seroprevalence was 27.6% in children under 5 years and rose to 73.8% in secondary school children and 74%
in adults. Antibody titres were higher in symptomatic individuals and declined over time since reported
COVID-19 symptoms, with the decline more marked for nucleocapsid titres.
Interpretation: In this tight-knit religious minority population in the UK, we report one of the highest SARS-
CoV-2 seroprevalence levels in the world to date, which was markedly higher than the reported 10% sero-
prevalence in London at the time of the study. In the context of this high force of infection, all age groups
experienced a high burden of infection. Actions to reduce the burden of disease in this and other minority
populations are urgently required.
Funding: This work was jointly funded by UKRI and NIHR [COV0335; MR/V027956/1], a donation from the
LSHTM Alumni COVID-19 response fund, HDR UK, the MRC and the Wellcome Trust.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)ent, Faculty of Infectious and
Medicine, Keppel Street, Lon-
s).
Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
The UK has been severely affected by the COVID-19 pandemic
with 66,197 deaths involving COVID-19 up to the 27th November
2020 [1]. In the UK the pandemic has disproportionately affected
minority ethnic populations with relatively higher numbers of posi-
tive cases and overrepresentation in admissions to hospitals and
Intensive Care Units and deaths [24]. Similar disparities have been
Research in context
Evidence before the study
In January 2021, we searched PubMed for articles on rates of
SARS-CoV-2 infection amongst ethnic minority groups and
amongst the Jewish population. Search teams included “COVID-
19”, “SARS-CoV-2”, seroprevalence, “ethnic minority”, and
“Jewish” with no language restrictions. We also searched UK
government documents on SARS-CoV-2 infection amongst
minority groups. By January 2021, a large number of authors
had reported that ethnic minority groups experienced higher
numbers of cases and increased hospitalisations due to COVID-
19. A small number of articles provided evidence that strictly-
Orthodox Jewish populations had experienced a high rate of
SARS-CoV-2 infection but extremely limited data was available
on overall population level rates of infection amongst specific
ethnic minority population groups. There was also limited data
on rates of infection amongst young children from ethnic
minority groups.
Added value of the study
We report findings from a population representative, house-
hold survey of SARS-CoV-2 infection amongst a UK strictly-
Orthodox Jewish population. We demonstrate an extremely
high seroprevalence rate of SARS-CoV-2 in this population
which is more than five times the estimated seroprevalence
nationally and five times the estimated seroprevalence in
London. In addition the large number of children in our sur-
vey, reflective of the underlying population structure, allows
us to demonstrate that in this setting there is a significant
burden of disease in all age groups with secondary school-
aged children having an equivalent seroprevalence to adults.
Implications of the available evidence
Our data provide clear evidence of the markedly disproportion-
ate impact of SARS-CoV-2 in minority populations. In this set-
ting infection occurs at high rates across all age groups
including pre-school, primary school and secondary school-age
children. Contextually appropriate measures to specifically
reduce the impact of SARS-CoV-2 amongst minority popula-
tions are urgently required.
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ity has been found to be higher in ethnic minority patients in both the
UK and USA [57]. The reasons for this disparity are unclear but are
likely multifactorial, reflecting both higher rates of infection resulting
from socio-economic factors including deprivation, less ability to
work from home, higher use of public transport and larger household
sizes, as well as increased severity of illness due to higher rates of
comorbidities or delayed access to care [8].
Most population based studies in the UK have focused on the
impact experienced by larger minority ethnic groups and not on
smaller groups, such as the Jewish community, who compromise
approximately 265,000 individuals or 0.5% of the UK's population [9].
In particular, strictly-Orthodox Jewish communities have anecdotally
reported high rates of infection, morbidity and hospitalisation during
the first wave of the UK pandemic [10]. These anecdotal reports are
supported by findings from Public Health England (PHE) which sug-
gests a higher risk from infection in the UK Jewish population and
higher rates of death due to COVID-19 in those self identifying as
Jewish with an age standardised mortality rates between March andMay for Jewish men over 65 years of 759 per 100,000 population,
much higher than in other religious groups [11]. This higher rate of
infection amongst the Jewish community might reflect socio-demo-
graphic differences compared to the general UK population. Strictly-
Orthodox Jewish communities have among the highest total fertility
rates in the UK, and experience high rates of overcrowded homes
and higher levels of socio-economic deprivation [12,13]. However,
after adjusting for socio-economic factors the hazard ratio for death
in Jewish men remained double that of Christian men suggesting that
routine socio-economic factors alone do not explain all of the
increased rate of infection seen in this community [11]. During the
first wave of the COVID-19 pandemic in Israel, strictly Orthodox Jew-
ish communities also reported higher incidence rates of COVID-19
than other socio-economically similar communities [14,15], or when
compared to households in Arab communities with similar sizes and
levels of crowding [15].
In Spring 2020, a tightly-knit strictly-Orthodox Jewish in the UK
community became aware that they appeared to be experiencing a
high burden of SARS-CoV-2. In view of this, and national data sug-
gesting a high burden of infection in the Jewish community and a
possible disproportionately high burden in the strictly-Orthodox
community, we co-developed a cross-sectional serological survey to
measure the burden of infection and identify factors associated with
transmission and to inform local control efforts.
2. Methods
2.1. Recruitment and survey methodology
Within a strictly-Orthodox Jewish community in the UK we con-
ducted a household-focused seroprevalence survey between late-
October and early December 2020 prior to the third national lock-
down. We obtained a comprehensive list of all resident households
within the community, held by our community collaborators. Each
household was assigned a unique identifier and we used simple-ran-
dom sampling to identify households for recruitment in to the study.
A second list of households where laboratory confirmed infections
were known to have occured (the ‘enriched’ list) was also included to
inform subsequent transmission models. Members of the study team
telephoned households to complete a standardised questionnaire,
including demographics, comorbidities, report of any previous pre-
sumed COVID-19 illness, previous PCR or serological testing for
SARS-CoV-2, access to care whilst unwell with a COVID-19 like ill-
ness, illness severity, attendance at work, educational or other com-
munity locations and travel overseas between February - November
2020. All households were visited within 10 days of completing the
questionnaire for collection of a serum sample except where a mem-
ber of the household reported active symptoms of COVID-19 in which
case the visit was scheduled for a minimum of 14 days after symptom
onset. All members of the household were eligible to be included
without age restrictions.
2.2. Laboratory analysis
Serum samples were analysed for the presence of IgG specific for
SARS CoV-2 trimeric spike protein (S), Receptor Binding Domain
(RBD) and nucleocapsid (N) antigens using a multiplex chemilumi-
nescence immunoassay (MSD, Rockville, MD) evaluated by our labo-
ratory as previously described [16,17].
2.3. Statistical analysis
For the purpose of this analysis, we considered a positive trimeric-
spike response as evidence of a prior SARS-CoV-2 infection as this tar-
get was shown to be the most sensitive and specific target in assay
validation16. We designed the survey to detect a seroprevalence of
Fig. 1. CONSORT diagram for recruitment into the study.
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clustering of infections at the household level and used a design-
effect of 2 to increase our sample size to adjust for this. We calculated
we would therefore need to recruit 1,730 participants. Assuming an
average household size of 6 we estimated this would be approxi-
mately 300 households.
To obtain unbiased estimates, we restricted our analysis to indi-
viduals from randomly selected households. Results related to the
‘enriched’ household dataset will be presented in future analyses. We
used cut-off values for the SARS-CoV-2 immunoassay from previous
validation studies for antibodies against trimeric-spike, nucleocapsid
and receptor binding domain.As assay cut-offs are well defined in
adults but less well defined in children, we conducted a sensitivity
analysis in which we considered thresholds for the trimeric-spike
assay of twice the previously defined limit.
We report the proportion of individuals who had a clinical illness
consistent with COVID-19 and the proportion of individuals who had
accessed testing prior to this survey. We calculated the seropreva-
lence of SARS-CoV-2 infection stratified by age and sex and adjusted
for clustering at the household level. Age was classified as pre-school
(0-4 years), primary education (5-10 years), secondary education
(11-18 years), adults and retirement (greater than 67 years). We cre-
ated a proxy variable which accounted for the number of community
events attended during the year (hereinafter ‘community-gather-
ings’) and a variable reflecting household overcrowding based on the
number of household residents and the number of bedrooms [18]. To
identify factors associated with SARS-CoV-2 infection we fitted a
multivariable random-effects logistic regression model adjusted for
clustering at the household level. We hypothesised that age, sex,
being unable to work from home, attendance at community events
and household overcrowding were a priori likely to be associated
with an increased risk of infection. We reported p-values for associa-
tions based on likelihood ratio-tests. We assessed relationships
between titres of antibodies against each of SARS-CoV-2 spike, recep-
tor binding domain and nucleocapsid in relation to individuals age,
sex, the presence or absence of a symptomatic illness, and for symp-
tomatic individuals the timing of their illness using a log-linear ran-
dom effects model. Analysis was performed in R version 4.02 and
random-effects models were fitted using lme4 version 1.1.26
2.4. Ethics
The study was approved by the London School of Hygiene & Tropi-
cal Medicine Ethics Committee (Ref 22532). Verbal informed consent
was given during the telephone survey and written consent provided
prior to phlebotomy. Parents provided written consent for children.
2.5. Role of the funding source
This work was jointly funded by UKRI and NIHR [COV0335; MR/
V027956/1], a donation from the LSHTM Alumni COVID-19 response
fund, HDR UK, the MRC and the Wellcome Trust.
The funders had no role in the design, conduct or analysis of the
study or the decision to publish.
3. Results
3.1. Enrollment and demographics
A total of 903 randomly selected households were approached, of
which 343 households comprising 1,759 individuals were enrolled
(Fig. 1). An additional 70 households with known cases of COVID-19
were provided by our community partners (referred to as ‘enriched
households’) were approached to participate, of which 28 households
comprising 183 individuals were enrolled (Supplementary Figure 3).
Serum samples were collected from 1242 individuals (70.6%) from283 randomly selected households and 137 individuals (74.9%) from
24 ‘enriched households.
The median household size was 5 (IQR 3-7, Range 1-14 cf. UK
median 2) [19] with a median of 3 bedrooms (IQR 2-5). The median
age of survey participants was 14 years (IQR 7-33, cd. UK median age
40 years) and 48.6% of participants were male (Supplementary Table
1). Of individuals who gave a serum sample, 48% were male and the
median age was 16 years (IQR 9-37).3.2. Routine testing for SARS-CoV-2
Amongst randomly selected households, a total of 446 individuals
(25.4%) had undertaken either PCR or serological testing for SARS-
CoV-2 and 182 individuals (10.3%) reported a positive result on at
least one test. Reported reasons for testing were because of symp-
tomatic disease or stated as “for other reasons” (Table 1). Individuals
who reported testing were older (median 31 IQR 15-46 vs 12 IQR 5-
25) and more likely to be male (52.7% vs 47.1%).
Overall 228 individuals (13%) underwent either PCR and/or sero-
logical testing because of symptomatic illness. A total of 191 symp-
tomatic individuals reported providing a sample for PCR with a swab
positivity rate of 59% (n = 113). By comparison 20 of 181 PCR tests
done for other reasons were positive (11%). Overall 182 individuals
(10.3%) reported already having received a positive test for SARS-
CoV-2 prior to the survey.
Serology on this cohort revealed an overall seroprevalence for
SARS-CoV-2 of 64.3% (95% CI 61.6-67.0%, 799/1,242). The seropreva-
lence varied by age between 27.6% (95% confidence interval (CI) 20.8
- 35.6%) for children aged under 5 years of age to 73.8% (95% CI 68.2 -
78.8%) amongst secondary school children and 74% (95% CI 70.0
-77.6%) adults (Fig. 2) (Supplementary Table 2). Seroprevalence was
significantly higher amongst men (68.8%, 95% CI 64.9 - 72.5%) than
women (59.7%, 95% CI 55.8 - 63.5%) (p = 0.001). Only three individuals
(2%) reported a previous positive PCR result but did not have detect-
able anti-spike antibodies. All three individuals had a positive PCR in
Table 1
Characteristics of the tests undertaken, stratified by presence of symptoms.
Tested for any reason Tested due to symptomatic illness Tested for any other reasons
Tested Positive Result Tested Positive Result Tested Positive Result
PCR 364 (20.7%) 133 (36.5%) 191 (10.9%) 113 (59.2%) 181 (10.3%) 20 (11.0%)
Serology 128 (7.3%) 55 (43.0%) 47 (2.7%) 31 (66.0%) 83 (4.7%) 25 (30.1%)
Total 446 (25.4%) 182 (40.8%) 228 (13.0%) 141 (61.8%) 238 (13.5%) 44 (18.5%)
Fig. 2. Age specific seroprevalence in participants in the study. Colours indicate male and female participants.
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they had not yet seroconverted at the time of sample collection. In a
multivariable random-effects logistic regression model, seropositivity
was associated with increasing age, male sex, household density and
whether and individual was was working or in education, but not
associated with attendance at community gatherings (Table 2). No
pre-existing comorbidities were associated with seropositivity.
Overall, 697 (37.5%) individuals reported an illness they
thought was consistent with COVID-19. There were clear peaks in
reported illness consistent with the first and second waves of
COVID-19 in the UK (Fig. 3). Of individuals reporting a suspectedTable 2





Age Young Children (0-4 years) 29.7% 0.07 (0
Primary Education (5-10 Years) 57.6% 0.36 (0
Secondary Education (11-18 Years) 73.4% 0.87 (0
Working age Adults (19-67) 74.9% 1
Retirement age adults (67+ Years) 58.3% 0.32 (0
Sex Female 63.4% 1
Male 69.2% 1.46 (1
Housing Not overcrowded 67.2% 1
Overcrowded 64.3% 0.86 (0
Employment and
Education Status
Neither Working nor in Education 68.5% 1
In Education 56.4% 0.49 (0
Working From Home 77.8% 1.78 (1
Working Outside Home 72.1% 1.25 (0
Number of Community Gatherings Attended 1 = 66.2% 1.02 (0
3 = 66.1%
5= 66.1%illness 49.8% were male and the median age was 28 (IQR 14-41). A
total of 16 (0.9%) individuals reported hospitalisation for COVID-
19 and a further three individuals were reported to have died of
COVID-19.
Overall 81.9 % of individuals who reported an illness consis-
tent with COVID-19 were sero-positive and 53.7% of asymptom-
atic individuals were sero-positive. Of cardinal symptoms of
COVID-19, self-reported cough (OR 3.0, 95% CI: 2.1-4.2), fever (OR
2.3, 95% CI: 1.6 -3.4) and loss of smell or taste (OR 11.8, 95% CI:
6.8 -20.6) were all associated with seropositivity. In the overall
population self-reported loss of smell or taste had a positiveood ratio test
sted Analysis Adjusted Analysis
CI) p-value* Marginal
Probability
aOR (95% CI) p-value*
.04 - 0.12) <0.001 31.5% 0.10 (0.05-0.20) <0.001
.24-0.54) 64.2% 0.77 (0.37-1.61)
.58-1.31) 77.4% 1.70 (0.89-3.27)
70.1% 1
.13-0.80) 54.7% 0.35 (0.14-0.91)
0.009 62.1% 1 0.002
.10 - 1.93) 69.0% 1.62 (1.18-2.24)
0.498 63.9% 1 0.412
.55 - 1.34) 67.2% 1.23 (0.74-2.06)
<0.001 69.7% 1 0.015
.35 - 0.67) 58.6% 0.45 (0.25-0.81)
.1 -2.87) 74.7% 1.40 (0.82-2.38)
.68-2.3) 66.3% 0.81 (0.41-1.58)
.98-1.06) 0.666 1 = 65.2% 1.04 (0.84-1.28) 0.702
3 = 65.4%
5 = 65.5%
Fig. 3. Self-reported COVID-19-like illness in participants in the study stratified by age and antibody status. The reduced number of self-reported cases in November is an arte-
fact reflecting the timing of the survey. Missing Anti-Spike antibody status occured when participants did not participate in phlebotomy after completing the survey. No phlebotomy
samples gave an inconclusive result.
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Table 3).
Titres of spike, receptor binding domain and nucleocapsid antibod-
ies were higher amongst individuals who reported a symptomatic ill-
ness (Fig. 4) (Table 3). Amongst symptomatic individuals titres
declined following time since reported symptomatic illness which was
more marked for nucleocapsid than for other targets (Supplementary
Figure 1).
4. Discussion
We found an extremely high seroprevalence of SARS-CoV-2 anti-
bodies in a strictly-Orthodox Jewish community in the UK. Our esti-
mate of 65% population seroprevalence is markedly higher than
recent estimates of 6.9% (95%CI 6.3-7.4%) nationally and 10.8% (95%
CI 9.3-12.5%) in London by random sampling in October by the Office
for National Statistics (ONS) [20]. Rapid declines in self-reported ill-
ness followed the introduction and adherence to lockdown in March,
demonstrating that even in this highly connected community such
measures are effective at reducing transmission. However over the
course of 2020, the overall seroprevalence in this tightly knit reli-
gious community reached levels similar to those seen in Manaus, Bra-
zil where a seroprevalence of more than 65% has been reported in
adults [21]. As our survey was completed by early December 2020,
prior to the subsequent winter case surge in London, it is likely that
the overall burden of infection in this community is now even higher.
Our estimates are amongst the highest sero-prevalence of SARS-
CoV-2 described anywhere in the world to date. In the UK other stud-
ies have also reported a higher seroprevalence of SARS-CoV-2
amongst ethnic minority individuals. In the nationally-representative
REACT-2 study in September 2020, seroprevalence amongst adults
from an ethnic minority was 7.9% compared to 3.6% for the white
population21. Whilst direct comparison with our study population is
limited by the absence of equivalently detailed sampling of other
populations, the overall pattern suggests a particularly high sero-
prevalence in our study population compared with ethnic minority
groups across the UK. The precise reasons why the burden of SARS-
CoV-2 has been so high in this population are unclear. In Israel,
strictly-Orthodox Jewish communities had markedly higher SARS-
CoV-2 PCR swab positive incidence rates compared to other socio-
economically similar communities during the first wave of the Israeli
epidemic [14,15], whilst seroprevalence following the first wave ofCOVID-19 was above 30% in many strictly-Orthodox communities
the United States [22]. Data from other sources suggest that lower
socio-economic status, ongoing need to travel to work and a greater
burden of pre-existing comorbidities, may all contribute to increased
risk of acquiring SARS-CoV-2.
In our study there was high seroprevalence in all age groups, with
the highest in working-age adults and older children where it
reached 74%. A strength of our study is the extremely high number of
children recruited, which reflects the higher total fertility rates
amongst strictly-Orthodox Jewish women compared to the UK aver-
age [12,13]. Seroprevalence in the youngest children was lower at
27% but rose rapidly to more than 50% amongst primary school-aged
children. The seroprevalence found in this group is approximately
four times that reported in a UK multicentre study on healthcare
worker children aged 2-15 years demonstrating the high rates of
infection in all age groups in the current study [23].
Seroprevalence was higher amongst men than women in our
study. Higher SARS-CoV-2 attack rates in men compared to women
have also been reported in some but not all otherstudies [24,25]. The
higher rate of infection amongst men might reflect biological differ-
ences, differences in comorbidities, differences in social mixing pat-
terns or other behaviours. As these differences might vary between
different ethnic minority groups it is possible that association
between sex and infection may not be consistent across all communi-
ties. We did not find any significant associations with reported atten-
dance at community events, workplace or household overcrowding
in this population which may be because of a true absence of effect,
or that due to the extremely high seroprevalence, the ability to detect
risk factors is limited. Further modelling work is planned to investi-
gate this in more detail.
The majority of reported symptomatic illness occurred during the
first and second waves of the COVID-19 pandemic mirroring case
reporting patterns seen across London and the UK. Just over 10% of
participants reported at least one swab test due to symptomatic ill-
ness since March, with an overall swab positivity rate of 59%. In line
with other studies, children were significantly less likely to report a
symptomatic illness [26,27] and this likely explains the higher rates
of routine testing amongst adults we observed in our study.
We found that antibody titres against spike and nucleocapsid pro-
teins declined at different rates, and in line with other studies
[16,28], that anti-nucleocapsid declined more quickly. If we had used
only anti-nucleocapsid antibodies as a marker of previous infection
Fig. 4. Log normalised antibody titres for anti-Spike, anti-Receptor Binding Domain and anti-Nucleocapsid. Each panel is stratified by reporting of COVID-19-like symptoms by
the participant. The shape shows the density of the distribution of samples.
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under-estimating the likely size of the epidemic that has occurred in
this population. Declines in anti-spike antibody titre were less
marked over time but it is still possible that we have under-estimated
the true seroprevalence in this population. Titres of both spike and
nucleocapsid antibodies were higher amongst individuals who
reported symptomatic illness.
Our study has a number of limitations. We recruited 38% of house-
holds that were approached and obtained serum samples from 70% of
study participants. This enrollment rate is similar to other nationalCOVID-19 household surveillance studies, such as the ONS COVD-19
Infection survey [29], suggesting it is unlikely to be a major source of
bias. Individuals who gave serum samples were slightly older than
those from whom serum was unavailable which may result in an
over-estimation of the overall population seroprevalence. We relied
on self-report of presumed COVID-19 illness which may be unreli-
able. However the timings of self reported illness match well to
national surveillance data and self-reported illness was strongly asso-
ciated with the presence of anti-spike antibodies suggesting that in
this population this was a reliable metric. Whilst household income
Table 3
Association between log-transformed antibody titres and participant characteristics.
Anti-Spike Antibody Titre Anti-Receptor Binding Domain Titre Anti-Nucleocapsid Antibody Titre
Beta 95% CI p-value Beta 95% CI p-value Beta 95% CI p-value
All Patients
Male Sex 0.383 0.142-0.623 0.002 0.412 0.193-0.640 <0.0013 0.314 0.120-0.509 0.002
Age (years) 0.006 -0.001-0.013 0.095 0.008 0.001-0.014 0.031 0.010 0.004-0.0160 0.001
Symptomatic Illness 1.25 0.975 - 1.532 <0.001 1.029 0.772-1.286 <0.001 1.020 0.796 - 1.244 <0.001
Symptomatic Individuals
Male Sex 0.137 -0.202 - 0.479 0.448 0.1411 -0.173 - 0.457 0.381 0.079 -0.212 - 0.372 0.612
Age (years) 0.023 0.013-0.033 <0.0001 0.021 0.012 - 0.030 <0.001 0.028 0.020 - 0.037 <0.001
Time since reported illness (days) -0.002 -0.004 - 0.000 0.041 -0.002 -0.004 - 0.000 0.022 0.005 -0.007 - -0.003 <0.001
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age this is partly offset by the wide network of community charities
and support networks [30]. We did not collect detailed data on socio-
economic status beyond household size and employment status and
so are not able to directly assess the importance of these factors on
seroprevalence in the community.
Although our study was conducted in a strictly-Orthodox Jewish
community, these communities share many characteristics with
other ethnic and religious minority groups including larger family
sizes, increased population density, children attending select schools,
regular attendance at communal events and gatherings, and English
as a second language. As such our findings are likely relevant to other
tightly-knit ethnic and religious minority groups in the UK and else-
where. Our work, conducted in direct collaboration with the commu-
nity, should be a model for understanding risk in minority
populations where there are no similar published data currently.
In conclusion, we found evidence for an extremely high rate of
SARS-CoV-2 infection in this specific community affecting individuals
of all ages. This provides further evidence that minority communities
in the UK and elsewhere are disproportionately affected by the
COVID-19 pandemic. The reasons for this remain unclear, although
are likely to be a complex interplay of socio-economic and behaviou-
ral factors. Further studies to better understand drivers of transmis-
sion in ethnic and religious minority populations, conducted
wherever possible in partnership with communities themselves, are
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